At Rome's Agostino Gemelli University Polyclinic Foundation, researchers have uncovered an unexpectedly simple intervention that could shift outcomes for women fighting advanced ovarian cancer: timing their meals around chemotherapy. The finding, presented at the American Society of Clinical Oncology meeting, suggests that fasting for 36 hours before chemotherapy and 24 hours after each treatment strengthens the tumor's response to the drugs—a discovery that costs nothing and demands no elaborate medical infrastructure.
Ovarian cancer remains one of the body's most stubborn adversaries. Despite surgical and chemical advances, women with stage 3 or stage 4 high-grade serous ovarian cancer still face grim statistics. This is precisely why Claudia Marchetti and her team at Gemelli studied 36 women receiving chemotherapy before surgery, splitting them into two groups: those who maintained normal eating patterns and those who fasted around their treatment cycles.
The results were striking. Women who fasted experienced significantly stronger tumor responses to chemotherapy. More tellingly, they remained cancer-free for 38 months on average—nearly 60 percent longer than the 24 months observed in women who ate normally. The mechanism appears deceptively elegant: fasting lowers insulin, a hormone that sends growth and survival signals directly to cancer cells. In the study, insulin levels rose among the control group but dropped sharply in the fasting group.
Marchetti emphasizes that this matters urgently. "Despite advancements in surgery and chemotherapy, patients with advanced ovarian cancer still face poor outcomes," she explained. "This study highlights the urgent need for safe, low-cost and easily implementable strategies that can enhance treatment efficacy and improve patient prognosis." In a healthcare landscape often dominated by expensive new drugs and complex protocols, a dietary intervention that women can implement themselves carries profound appeal—both economically and practically.
The science underlying the observation is still being mapped. Researchers continue investigating how fasting influences the broader body, immune function, and the intricate dialogue between nutrition and chemotherapy response. These preliminary findings have sparked plans for larger clinical trials, which will test whether this modest intervention holds up at scale and across more diverse populations.
What makes this discovery particularly resonant is its accessibility. Unlike breakthrough drugs requiring years of development and months of insurance negotiations, short-term fasting is available immediately to any woman currently undergoing chemotherapy for advanced ovarian cancer—something she can discuss with her oncologist and potentially begin at her next infusion. The approach demands no new equipment, no side effects beyond hunger, and no cost beyond discipline.
That said, the study remains preliminary. Thirty-six patients is a meaningful but modest sample size, and more research must confirm whether these benefits persist in larger populations and clarify which women might benefit most. The researchers are methodical about this, continuing their work without overstating the case.
Still, in a disease where survival measured in years rather than decades is common, a 14-month extension of cancer-free survival represents hope grounded in data—not hype. As larger trials unfold, this simple timing shift may quietly become part of how women and their doctors approach one of medicine's most challenging cancers.